Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 von Hippel-Lindau Disease 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Cisplatin 46 Carboplatin 43 pembrolizumab 39 Paclitaxel 38 Gemcitabine 27 Radiotherapy 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 18 Radiotherapy, Intensity-Modulated 17 Docetaxel 17 Cetuximab 16 Specimen Handling 15 Nivolumab 15 Cyclophosphamide 14 durvalumab 13 Fluorouracil 13 Sorafenib 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 10 Sunitinib 9 Platinum 9 osimertinib 8 Radiation 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Capecitabine 8 1,2-diaminocyclohexaneplatinum II citrate 8 Ipilimumab 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07227402 2026-03-16

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡